An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC)

4577 Background: Brivanib is an orally available dual inhibitor of vascular endothelial growth factor and fibroblast growth factor (FGF) signaling. FGF pathway activation is of increasing importance in the setting of liver fibrosis and HCC. This phase II study aimed to assess the efficacy and safety... View More